Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6200MR)

This product GTTS-WQ6200MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6200MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3661MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8146MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ10639MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ6148MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ14626MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ11340MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ4390MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12165MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW